Evidence map›Paper›PMID 26371460›Full record

ReviewCurrent opinion in HIV and AIDS2015

The HIV treatment cascade in acutely infected people: informing global guidelines.

Sarah E Rutstein, Christopher J Sellers, Jintanat Ananworanich, Myron S Cohen

Abstract readReview
In one paragraph

Review in Current opinion in HIV and AIDS, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sarah E RutsteinaDepartment of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA bDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA cU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring dHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland eDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA *Sarah E. Rutstein and Christopher J. Sellers contributed equally to the writing of this article.
Christopher J Sellers
Jintanat Ananworanich
Myron S Cohen

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008719 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DARVILLE, TONI, DESHMUKH, MOHANISH P · 1999 to 2023
$15.1M
Training in Sexually Transmitted Infections and HIVT32AI007001 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SENA-SOBERANO, ARLENE C. · 1985 to 2025
$10.9M
Training in Infectious Disease Epidemiology (TIDE)T32AI070114 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian W Pence · 2007 to 2026
$4.0M
The Latent HIV Reservoir in Early-treated Thai ChildrenR01AI114236 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI PUTHANAKIT, THANYAWEE, ROBB, MERLIN L · 2014 to 2018
$2.8M
Reaching Unaware Sexual and Social Contacts to Interrupt Ongoing HIV TransmissionR01AI114320 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MILLER, WILLIAM C, POWERS, KIMBERLY A · 2014 to 2017
$2.5M
Optimizing HIV Therapy: virological monitoring, adherence & cost-effectivenessF30MH098731 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUTSTEIN, SARAH E. · 2012 to 2016
$201k
NIAID NIH HHS 5T32AI070114-08NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI50410NIAID NIH HHS R01 AI114236NIAID NIH HHS R01 AI114320NIAID NIH HHS T32 AI070114NIGMS NIH HHS T32 GM008719NIMH NIH HHS F30 MH098731
6 · The paper itself

Abstract

purpose of reviewAcute and early HIV (AHI) is a pivotal time during HIV infection, yet there remain major shortfalls in diagnosis, linkage to care, and antiretroviral therapy (ART) initiation during AHI. We introduce an AHI-specific cascade, review recent evidence pertaining to the unique challenges of AHI, and discuss strategies for improving individual and public health outcomes. RECENT

findingsPresentation during AHI is common. Expanding use of fourth-generation testing and pooled nucleic acid amplification testing has led to improved AHI detection in resource-wealthy settings. Technologies capable of AHI diagnosis are rare in resource-limited settings; further development of point-of-care devices and utilization of targeted screening is needed. Rapid ART initiation during AHI limits reservoir seeding, preserves immunity, and prevents transmission. Reporting of AHI cascade outcomes is limited, but new evidence suggests that impressive rates of diagnosis, linkage to care, rapid ART initiation, and viral suppression can be achieved. SUMMARY: With advancements in AHI diagnostics and strong evidence for the therapeutic and prevention benefits of ART initiated during AHI, improving AHI cascade outcomes is both crucial and feasible. HIV guidelines should recommend diagnostic algorithms capable of detecting AHI and prescribe rapid, universal ART initiation during AHI.

Indexed as

Health PolicyAnti-Retroviral AgentsDeveloped CountriesDeveloping CountriesDiagnostic Tests, RoutineDisease Transmission, InfectiousEarly DiagnosisGlobal HealthHIV InfectionsHumansSecondary PreventionAnti-Retroviral Agents

Identifiers

PMID26371460
PMCPMC4739850

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.